BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 29357274)

  • 1. Glioblastoma: Vascular Habitats Detected at Preoperative Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging Predict Survival.
    Juan-Albarracín J; Fuster-Garcia E; Pérez-Girbés A; Aparici-Robles F; Alberich-Bayarri Á; Revert-Ventura A; Martí-Bonmatí L; García-Gómez JM
    Radiology; 2018 Jun; 287(3):944-954. PubMed ID: 29357274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Robust association between vascular habitats and patient prognosis in glioblastoma: An international multicenter study.
    Del Mar Álvarez-Torres M; Juan-Albarracín J; Fuster-Garcia E; Bellvís-Bataller F; Lorente D; Reynés G; Font de Mora J; Aparici-Robles F; Botella C; Muñoz-Langa J; Faubel R; Asensio-Cuesta S; García-Ferrando GA; Chelebian E; Auger C; Pineda J; Rovira A; Oleaga L; Mollà-Olmos E; Revert AJ; Tshibanda L; Crisi G; Emblem KE; Martin D; Due-Tønnessen P; Meling TR; Filice S; Sáez C; García-Gómez JM
    J Magn Reson Imaging; 2020 May; 51(5):1478-1486. PubMed ID: 31654541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular habitat analysis based on dynamic susceptibility contrast perfusion MRI predicts IDH mutation status and prognosis in high-grade gliomas.
    Wu H; Tong H; Du X; Guo H; Ma Q; Zhang Y; Zhou X; Liu H; Wang S; Fang J; Zhang W
    Eur Radiol; 2020 Jun; 30(6):3254-3265. PubMed ID: 32078014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma.
    Liu X; Mangla R; Tian W; Qiu X; Li D; Walter KA; Ekholm S; Johnson MD
    J Neurooncol; 2017 Dec; 135(3):553-560. PubMed ID: 28889246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiomic Analysis Reveals Prognostic Information in T1-Weighted Baseline Magnetic Resonance Imaging in Patients With Glioblastoma.
    Ingrisch M; Schneider MJ; Nörenberg D; Negrao de Figueiredo G; Maier-Hein K; Suchorska B; Schüller U; Albert N; Brückmann H; Reiser M; Tonn JC; Ertl-Wagner B
    Invest Radiol; 2017 Jun; 52(6):360-366. PubMed ID: 28079702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vessel size and perfusion-derived vascular habitat refines prediction of treatment failure to bevacizumab in recurrent glioblastomas: validation in a prospective cohort.
    Kim M; Park JE; Yoon SK; Kim N; Kim YH; Kim JH; Kim HS
    Eur Radiol; 2023 Jun; 33(6):4475-4485. PubMed ID: 36242633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI.
    Romano A; Pasquini L; Di Napoli A; Tavanti F; Boellis A; Rossi Espagnet MC; Minniti G; Bozzao A
    J Neurooncol; 2018 Sep; 139(2):455-460. PubMed ID: 29721752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: Comparison of intraindividually matched T1 - and T2 (*) -based bolus techniques.
    Bonekamp D; Deike K; Wiestler B; Wick W; Bendszus M; Radbruch A; Heiland S
    J Magn Reson Imaging; 2015 Jul; 42(1):87-96. PubMed ID: 25244574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
    Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between perfusion computed tomography and dynamic contrast-enhanced magnetic resonance imaging in assessing glioblastoma microvasculature.
    Jia ZZ; Shi W; Shi JL; Shen DD; Gu HM; Zhou XJ
    Eur J Radiol; 2017 Feb; 87():120-124. PubMed ID: 28034567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of Dynamic Contrast-Enhanced MRI-Derived Pharmacokinetic Variables in Glioblastoma Patients: Analysis of Contrast-Enhancing Lesions and Non-Enhancing T2 High-Signal Intensity Lesions.
    Kang Y; Hong EK; Rhim JH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SW; Choi SH
    Korean J Radiol; 2020 Jun; 21(6):707-716. PubMed ID: 32410409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of Glioblastoma and Solitary Brain Metastasis by Gradient of Relative Cerebral Blood Volume in the Peritumoral Brain Zone Derived from Dynamic Susceptibility Contrast Perfusion Magnetic Resonance Imaging.
    She D; Xing Z; Cao D
    J Comput Assist Tomogr; 2019; 43(1):13-17. PubMed ID: 30015801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiomic Profiling of Glioblastoma: Identifying an Imaging Predictor of Patient Survival with Improved Performance over Established Clinical and Radiologic Risk Models.
    Kickingereder P; Burth S; Wick A; Götz M; Eidel O; Schlemmer HP; Maier-Hein KH; Wick W; Bendszus M; Radbruch A; Bonekamp D
    Radiology; 2016 Sep; 280(3):880-9. PubMed ID: 27326665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers.
    Jain R; Poisson L; Narang J; Gutman D; Scarpace L; Hwang SN; Holder C; Wintermark M; Colen RR; Kirby J; Freymann J; Brat DJ; Jaffe C; Mikkelsen T
    Radiology; 2013 Apr; 267(1):212-20. PubMed ID: 23238158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor.
    Jain R; Poisson LM; Gutman D; Scarpace L; Hwang SN; Holder CA; Wintermark M; Rao A; Colen RR; Kirby J; Freymann J; Jaffe CC; Mikkelsen T; Flanders A
    Radiology; 2014 Aug; 272(2):484-93. PubMed ID: 24646147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic examination performance by using microvascular leakage, cerebral blood volume, and blood flow derived from 3-T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in the differentiation of glioblastoma multiforme and brain metastasis.
    Server A; Orheim TE; Graff BA; Josefsen R; Kumar T; Nakstad PH
    Neuroradiology; 2011 May; 53(5):319-30. PubMed ID: 20625709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of pseudoprogression in post-treatment glioblastoma using dynamic susceptibility contrast-derived oxygenation and microvascular transit time heterogeneity measures.
    Park JE; Kim HS; Kim N; Borra R; Mouridsen K; Hansen MB; Kim YH; Hong CK; Kim JH
    Eur Radiol; 2024 May; 34(5):3061-3073. PubMed ID: 37848773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor Surface Regularity at MR Imaging Predicts Survival and Response to Surgery in Patients with Glioblastoma.
    Pérez-Beteta J; Molina-García D; Ortiz-Alhambra JA; Fernández-Romero A; Luque B; Arregui E; Calvo M; Borrás JM; Meléndez B; Rodríguez de Lope Á; Moreno de la Presa R; Iglesias Bayo L; Barcia JA; Martino J; Velásquez C; Asenjo B; Benavides M; Herruzo I; Revert A; Arana E; Pérez-García VM
    Radiology; 2018 Jul; 288(1):218-225. PubMed ID: 29924716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deep Learning of Time-Signal Intensity Curves from Dynamic Susceptibility Contrast Imaging Enables Tissue Labeling and Prediction of Survival in Glioblastoma.
    Yun J; Yun S; Park JE; Cheong EN; Park SY; Kim N; Kim HS
    AJNR Am J Neuroradiol; 2023 May; 44(5):543-552. PubMed ID: 37105676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher vascularity at infiltrated peripheral edema differentiates proneural glioblastoma subtype.
    Chelebian E; Fuster-Garcia E; Álvarez-Torres MDM; Juan-Albarracín J; García-Gómez JM
    PLoS One; 2020; 15(10):e0232500. PubMed ID: 33052913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.